Whalen Wealth Management Inc. Makes New $566,000 Investment in Avantor, Inc. (NYSE:AVTR)

Whalen Wealth Management Inc. purchased a new position in shares of Avantor, Inc. (NYSE:AVTR) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 26,860 shares of the company’s stock, valued at approximately $566,000.

Other hedge funds have also made changes to their positions in the company. MassMutual Private Wealth & Trust FSB increased its position in Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock worth $26,000 after purchasing an additional 625 shares during the last quarter. UMB Bank n.a. purchased a new stake in shares of Avantor during the 3rd quarter valued at $49,000. Nisa Investment Advisors LLC raised its position in shares of Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after buying an additional 835 shares during the period. GAMMA Investing LLC raised its position in shares of Avantor by 89.9% in the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after buying an additional 1,285 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its holdings in Avantor by 278.0% in the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,031 shares of the company’s stock valued at $130,000 after acquiring an additional 3,700 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Stock Up 1.6 %

Shares of Avantor stock opened at $22.12 on Thursday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. Avantor, Inc. has a 1-year low of $19.59 and a 1-year high of $28.00. The business has a 50-day moving average of $21.46 and a 200-day moving average of $23.39. The company has a market capitalization of $15.05 billion, a PE ratio of 48.08, a P/E/G ratio of 3.48 and a beta of 1.28.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Barclays cut their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Raymond James cut their price target on shares of Avantor from $29.00 to $26.00 and set an “outperform” rating on the stock in a report on Tuesday. UBS Group reiterated a “neutral” rating and set a $25.00 price objective (down from $29.00) on shares of Avantor in a research note on Friday, January 17th. Wells Fargo & Company cut their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $34.00 target price on shares of Avantor in a report on Thursday, September 26th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.